The natural hormones, estrogen and progesterone, influence endometrial development and maturation during the menstrual cycle. Estrogen stimulates endometrial growth and synthesis and release of plasminogen activators (PAs), whereas progesterone causes secretory changes inhibiting PA activation. Estrogen and progesterone receptors localized in the endothelial and smooth muscle cells of the vessel wall cause differences
in response of veins and arteries to sex steroids (1) . The influence of natural hormones during the menstrual cycle on coagulation and fibrinolysis are varied. Factor VIII (FVIII) and antithrombin III (ATIII) showed no significant variation including fibrinogen throughout the menstrual cycle (2) while others reported reduced (3) and significantly increased fibrinogen level (4) in the luteal phase. Strong cyclic variation of fibrinogen and von Willebrand factor (vWF) with peak levels in the luteal phase (5) , no changes (6) but lower levels during menstruation compared to days 5 to 11 were reported by Miller and colleagues (7) . Lower plasma urokinase PA (u-PA) in the post-ovulatory phase of the cycle with no change in tissue PA (t-PA) and its inhibitor plasminogen activator inhibitor-1 (PAI-1) have been reported (8) . Coagulation activation and fibrinolysis were not enhanced between Summary: Coagulation and fibrinolytic variables including platelet function and endogenous fibrinolytic response were determined in 30 normal healthy women volunteers not on any known medication during the period of study. They were between 18 years and 38 years old and had normal menstrual cycles of between 28 days and 30 days. Blood samples were obtained within one menstrual cycle and after having fasted overnight within days 1 to 3 (menstruation), 5 to 9 (follicular), 10 to 14 (mid-cycle), and 21 to 26 (luteal) of the menstrual cycle. Analysis of variance (ANOVA) showed no significant differences in the hemostatic parameters studied between the phases of the menstrual cycle except for a reduced D-dimer level at midcycle. Significant fibrinolytic response was seen after venous occlusion but they were not significantly different between the phases of the menstrual cycle. The women were then divided into either normal weight (n=22) or overweight (n=8) according to World Health Organization (WHO) classification and the data reanalyzed. Elevated tissue plasminogen activator antigen and plasminogen activator inhibitor-1 levels except at menstruation and total protein S except at follicular phase were observed in overweight women together with increased plasminogen level only at luteal phase. Significant endogenous fibrinolytic response seen during the menstrual cycle was not different between normal and overweight women. The study demonstrated that systemic coagulation, fibrinolysis, and platelet function were probably not influenced by natural hormonal changes occurring during the menstrual cycle except for an associated reduced fibrinolytic state at mid-cycle. The hemostatic system in this small group of healthy overweight women studied appeared to be physiologically compromised. Key Words: Hemostasis-Menstrual cycle.
the follicular and luteal phases, but platelet function was altered periodically (4) . Increased body mass index (BMI) was associated with an increased risk of heart failure and is a risk marker of venous thrombotic disease (9) . The World Health Organization (WHO) international classification (10) of weight status (BMI) defined normal weight as between 18.5 and 24.9 kg/m 2 , overweight as between 25 to 29.9 kg/m 2 , and obese as 30 kg/m 2 or greater. Obesity and thrombosis are associated with disordered hemostasis, but the mechanism is incompletely understood. Obese subjects tend to have higher levels of fibrinogen, FVII, FVIII, vWF, PAI-1 (11, 12) and t-PA, and protein C compared to levels in non-obese subjects (12) .
The purpose of the study is to determine the presence of any the natural hormonal influence on hemostasis and endogenous fibrinolytic response potential at different phases of the menstrual cycle in a group of normal and overweight healthy Singapore women.
MATERIALS AND METHODS
The study received approval from the Hospital's Research Ethics Committee, written consent was obtained from each subject.
Subjects
Thirty normal healthy women aged between 18 years and 38 years (mean 22.8 ± 5.2 years) who have completed blood samplings in one menstrual cycle within days 1 to 3 (menstruation), 5 to 9 (follicular), 10 to 14 (mid-cycle), and 21 to 26 (luteal) and a menstrual cycle of between 28 and 30 days were recruited to the study. They comprised volunteers recruited from medical staff and undergraduates who were interviewed and reported to have no significant medical history. They were not on any known medication during the study period. The women were later divided according to the WHO classification of normal weight (n = 22, BMI mean 20.3 ± 2.0 kg/m 2 ) and overweight (n = 8, BMI mean 29.9 ± 4.7 kg/m 2 ).
Sample Collection and Venous Occlusion Studies
Blood sampling was performed between 0900 hours and 1100 hours after an overnight fast and blood from a clean venupuncture of the antecubital vein was obtained after the subjects rested for at least 20 minutes. The height, weight, and blood pressure were recorded. Nine parts of blood were mixed with 1 part of 0.129 M trisodium citrate (Merck, Indianapolis) containing 0.21 M HEPES (Sigma) in cold plastic tubes. Citrated blood was used for thrombelastography (TEG) hemostatic status screen and the remainder spun immediately at 2000g for 15 minutes in a refrigerated centrifuge. For plasma t-PA activity assay, 0.5 mL aliquot was acid-treated as described previously (13) . Both acid-treated and untreated plasma aliquots were stored at -70°C until assayed. For venous occlusion studies, a blood pressure cuff on the adjacent arm was maintained midway between the systolic and diastolic reading for 10 minutes and blood obtained from this arm was processed as described previously.
Coagulation Factors, Inhibitors, and Activation Assays
Hemostatic status was determined using the computerized Thrombelastograph (cTEG) (Haemoscope, USA) (14) ; Fibrinogen (Clauss), Factor VII and Factor VIII, one-stage assays with deficient plasma from Diagnostic Reagents, (UK); von Willebrand Factor (vWF) (in-house ELISA with antisera from Dako (Denmark); in-house chromogenic substrate assay for ATIII activity, Thrombin-antithrombin (TAT)-complex and prothrombin fragment 1+2 (F 1+2 )(Behring, Marburg, Germany).
Platelet Function
Platelets were counted in the electronic Coulter Counter Zm/Multisizer II and β-thromboglobulin (β-TG), ELISA kit from Stago (France).
Plasminogen Activators, Inhibitors, and Proteins
t-PA activity (13); t-PA antigen, u-PA antigen, protein C antigen (American Diagnostics, USA); u-PA activity (15); PAI-1 activity (16); PAI-1 antigen (Zymutest, France); plasminogen (chromogenic substrate assay); D-dimer (Stago, France); and total protein S (in-house ELISA) were measured.
Primary international standards obtained from the National Institute for Biological and Standards Control (NIBSC), Hempstead, England were used for the following assays; fibrinogen, factors VII and VIII, vWF, t-PA, u-PA and PAI-1 activities, plasminogen, ATIII, and total protein S.
Statistical Analysis
The statistical package for social sciences (SPSS) was used. One-way analysis of variance (ANOVA) was used to compare the hemostatic parameters studied between different phases of the menstrual cycle in both normal and overweight women. Mann Whitney and non-parametric independent t test were used to compare hemostatic parameters and fibrinolytic response to venous occlusion between normal and overweight women and between each phase of the menstrual cycle. A p value less than 0.05 was considered statistically significant.
RESULTS
The results of coagulation, fibrinolysis, and platelet function at different phases of the menstrual cycle are shown in Table 1 and the fibrinolytic response ratio is shown in Table 2 . Comparison between normal weight and overweight women for hemostasis at different phases of the menstrual cycle was performed and only significant differences are shown in Table 3 and the fibrinolytic response ratio in Table 4 .
Hemostatic Parameters at Different Phases of the Menstrual Cycle
No statistical significant differences in coagulation and fibrinolytic variables and platelet function between the phases of the menstrual cycle was seen except for D-dimer level (mean, 182 ± 72 ng/mL) at days 10 to 14, which showed a significant decrease (p=0.04) compared to the other menstrual periods in the 30 healthy women studied.
Endogenous Fibrinolytic Response Potential
Post-occlusion levels of t-PA and u-PA were corrected between pre-and post-hematocrit levels and the response ratio calculated. Significant fibrinolytic response ratio for t-PA was seen in all phases of the menstrual cycle but no significant differences could be demonstrated between the phases of the menstrual cycle. Moreover, no significant response was seen in u-PA levels after occlusion.
Due to the insignificant differences in hemostatic parameters studied, the women were divided into those with normal weight with BMI of less than 25 kg/m 2 (n=22) and overweight with BMI greater than 25 kg/m 2 (n=8) and the data recalculated. 
Significant Hemostatic Parameters Between Normal and Overweight Women
Only the significant variables studied between normal and overweight women are shown. In overweight women, t-PA antigen levels were elevated at all phases of the menstrual cycle with elevated PAI-1 levels seen only between follicular phase and luteal phase. Elevated total protein S reached significance only between mid-cycle, luteal phase, and at menstruation in overweight women. Plasminogen was increased only at the luteal phase and this can contribute as a substrate for potential fibrinolytic activity to enhanced t-PA and its inhibitor PAI-1 levels seen. No other significant hemostatic variables studied could be demonstrated between each phase of the menstrual cycle in normal and overweight women.
Endogenous Fibrinolytic Response Between Normal and Overweight Women
Significant endogenous fibrinolytic responses after occlusion for t-PA levels were seen in both groups of women at all phases of the menstrual cycle studied. However, no significant differences in fibrinolytic response were seen between normal and overweight women at all respective phases of the menstrual cycle. No significant response after occlusion for u-PA levels in both groups of women were also seen.
DISCUSSION
The study of hemostatic and fibrinolytic variables including platelet function in 30 normal subjects at menstruation (day 1-3), follicular (day 5-9), mid-cycle (day [10] [11] [12] [13] [14] , and luteal (day 21-16) phases of the menstrual cycle showed no significant variation between the phases of the menstrual cycle except that at midcycle (day 10-14), reduced D-dimer level was seen. The reduced D-dimer level at mid-cycle suggested a lower systemic fibrinolytic activity at this phase of the menstrual cycle that was associated with reduced fibrinolytic activity at the endometrium tissue level reported previously (17) . Furthermore, significant endogenous fibrinolytic response (post-occlusion) for t-PA was seen but no significant differences between the phases of the menstrual cycle could be demonstrated. In view of this, the women were then divided into those who had normal body weight and overweight according to the WHO classification (10) . In overweight women t-PA antigen remained elevated with PAI-1 levels increased except at menstruation and total protein S remained elevated except during the follicular phase with plasminogen levels increased only at the luteal phase when compared to relevant phases in the menstrual cycle of normal weight women. The elevated total protein S seen (cofactor for protein C) and plasminogen, respectively, suggests an antithrombotic and at luteal phase a fibrinolysis potential effect in overweight women before the onset of menstruation. Hemostatic variables in menstrual cycle has been studied previously at different times of the cycle and to our knowledge not compared to BMI. Cyclic variation in fibrinogen and vWF with peaks in the luteal phase have been reported (4,5), reduced fibrinogen (3) with lower levels during menstruation (7) while earlier studies showed no significant changes in fibrinogen, FVIII, and ATIII (2); recently, no variation in both vWF and FVIII during the normal cycle was seen (6) . Plasma u-PA has been reported to be reduced in the post-ovulatory phase with no change in t-PA and PAI-1 concentration at preor post-ovulatory phases (8) . We could not demonstrate the previous changes in our cohorts studied at different phases of the menstrual cycle except for a reduced D-dimer level at the midcycle, which suggested a reduced fibrinolytic state. Several studies have shown elevated levels of prothrombotic factors in obese subjects for fibrinogen, FVII, FVIII, vWF, and PAI-1 (11, 12) . We were not able to demonstrate changes in the previous findings in our small group of overweight women studied except for elevated t-PA antigen, and PAI-1 levels except at menstruation with enhanced total protein S except at the follicular phase and plasminogen only at the luteal phase of the menstrual cycle when compared with normal weight women at the respective phases of the menstrual cycle. Production of PAI-1 by adipose tissue, particularly by fat from omentum, and the suggested role of elevated PAI-1 expression in human obesity could be involved in mechanisms that control adipose tissue development; this has been supported by the mice study (18) .
Enhanced endogenous fibrinolytic response potential with venous-occlusion test in normal males and females was reported by us previously (19) . Similarly, in this study, enhanced fibrinolytic response was seen but differences between various phases of the menstrual cycle in both normal and overweight women could not be demonstrated. In a study of Chinese healthy volunteers, short-term high fat diet showed a significantly enhanced fibrinolytic response but less than that before treatment, indicating an impaired fibrinolytic response to stress (20) . This is in contrast to our study of overweight women who showed no significant differences in fibrinolytic response compared with that in normal weight women.
This study demonstrated that systemic coagulation and fibrinolytic variables and platelet function were not influenced by natural hormonal changes occurring during the menstrual cycle except for an association of reduced fibrinolytic state at mid-cycle. The hemostasis analysis indicates that hormonal influence is probably localized at the endometrium level. The elevated t-PA and PAI-1 levels could be a vascular effect of increased synthesis or an acute phase reactant protein response to the overweight condition and not directly under hormonal influence because levels were elevated throughout the menstrual cycle except for the PAI-1 level at the menstrual phase. The fibrinolytic and inhibitor system in the small group of healthy overweight women studied appeared to be physiologically compromised. However, a larger study is required to confirm these findings.
